Table 1 Clinical characteristics of MM patients
N° (%) | |
|---|---|
(N = 15) | |
Age at transplant, (years) | |
Median (range) | 58 (43–70) |
Gender | |
Male | 9 (60) |
Female | 6 (40) |
Paraprotein isotype | |
IgG/κ | 7 (47) |
IgG/λ | 3 (20) |
IgA/κ | 1(7) |
Light chain/κ | 2 (13) |
Light chain/λ | 1 (7) |
Nonsecretory | 1 (7) |
Frontline MM therapy | |
VTD | 14 (93) |
VCD | 1 (7) |
Stem Cells Mobilization procedure | |
G-CSF steady-state | 10 (67) |
Vinorelbine-Cyclophosphamide | 2 (13) |
High-dose Cyclophosphamide | 3 (20) |
Total CD34 + cells yield (× 106/kg) | |
Median (range) | 4.54 (2.6–8.4) |
High-dose conditioning (Melphalan 200 mg/m2) | |
Total mg.s of Mel delivered (median, range) | 376 (278–430) |
Total CD34 + cells infused (× 106/kg) | |
Median (range) | 2.9 (2.4–4.7) |
Hemogram at day 0 [median (range)] | |
ANC × 109/L | 4.0 (3.7–6.4) |
Platelets × 109/L | 220 (123–310) |
ALC × 109/L | 0.2 (0.0–0.5) |
Hemocomponents support up to discharge | |
RBC units transfused (median, range) | 0 (0–3) |
Platelet units transfused (median, range) | 1 (0–3) |
Transplant-related Toxicity (G1-G2)* | |
Febrile neutropenia | 2 (13) |
Fever of unknown origin | 3 (20) |
Microbiologically documented infection | 2 (13) |
Mucositis | 7 (47) |
Diarrhoea | 6 (40) |
Other adverse events | 1 (7) |